Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by SetPoint Medical

SetPoint Medical to Present Data at ACR Convergence 2025 Demonstrating Sustained Efficacy and Safety for the SetPoint System to Treat Rheumatoid Arthritis
From SetPoint Medical
Via Business Wire
SetPoint Medical Raises $140 Million in Private Financing and Expands Leadership Team to Support Commercialization of Rheumatoid Arthritis Therapy
From SetPoint Medical
Via Business Wire
SetPoint Medical Receives FDA Approval for Novel Neuroimmune Modulation Therapy for Rheumatoid Arthritis
From SetPoint Medical
Via Business Wire
SetPoint Medical Receives Clinical Research Award at EULAR 2025 Congress
From SetPoint Medical
Via Business Wire
SetPoint Medical Appoints Tyler Binney to Its Board of Directors
From SetPoint Medical
Via Business Wire
SetPoint Medical Announces Filing of Premarket Approval (PMA) Application to the U.S. Food and Drug Administration (FDA) for Novel Neuroimmune Modulation Device for the Treatment of Rheumatoid Arthritis
From SetPoint Medical
Via Business Wire
SetPoint Medical Announces Late-Breaking Data from RESET-RA Study at ACR Convergence 2024
From SetPoint Medical
Via Business Wire
SetPoint Medical Receives FDA’s IDE Approval for U.S. Pilot Study of Neuroimmune Modulation Platform in Adults with Relapsing-Remitting Multiple Sclerosis
From SetPoint Medical
Via Business Wire
SetPoint Medical Announces Positive Topline Results from Landmark RESET-RA Study Evaluating Neuroimmune Modulation for the Treatment of Rheumatoid Arthritis
From SetPoint Medical
Via Business Wire
SetPoint Medical Accepted into FDA Total Product Life Cycle Advisory Program for Development of its Neuroimmune Modulation Platform for the Treatment of Multiple Sclerosis
From SetPoint Medical
Via Business Wire
SetPoint Medical Receives FDA Breakthrough Device Designation for its Neuroimmune Modulation Platform for the Treatment of Multiple Sclerosis
From SetPoint Medical
Via Business Wire
SetPoint Medical Announces Publication of Data for Neuroimmune Modulation to Treat Crohn's Disease in Journal of Crohn's and Colitis
From SetPoint Medical
Via Business Wire
SetPoint Medical Appoints Rohan Seth as Chief Financial Officer
From SetPoint Medical
Via Business Wire
SetPoint Medical Announces Expanded $65M Credit Facility to Support Development of the Company’s Novel Platform for Rheumatoid Arthritis
From SetPoint Medical
Via Business Wire
Tickers RWAY
SetPoint Medical Announces $80M Preferred Stock Financing to Advance Company’s Novel Treatment for Autoimmune Diseases
From SetPoint Medical
Via Business Wire
First Patient Enrolled in Stage 2 of Pivotal Study of SetPoint Medical’s Pioneering Technology for the Treatment of Rheumatoid Arthritis
From SetPoint Medical
Via Business Wire
SetPoint Medical Announces FDA Approval for Continuation of the RESET-RA Pivotal Study
From SetPoint Medical
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.